ARMC9

Across TCGA pan-cancer cohorts, ARMC9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARMC9 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher ARMC9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARMC9 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SARC, UCEC, and SKCM are the cancer types where ARMC9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.142	0.761	<.001	6	view →
BRCA	OS	Median	All	0.750	0.963	.031	4	view →
BLCA	OS	Median	III,IV	0.770	0.341	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARMC9–SARC (DFS)

Open the SARC breakdown →